DOCSLIB.ORG

Network Spring/Summer 2006 News, Views and Information from the Medical Research Council

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Network Spring/Summer 2006 News, Views and Information from the Medical Research Council network Spring/Summer 2006 News, views and information from the Medical Research Council In this issue Budget heralds radical new Flu science A look at the NIMR’s approach to UK medical research flu surveillance work health benefits:“This Budget confirmed vividly page 4 Gordon Brown’s commitment to research, especially medical research. It represents a real Biomarkers chance for substantial improvement for the workshop funding arrangements in the UK, facilitating the Will biomarkers interaction between basic and clinical research.” change the future Colin Blakemore observed that the Chancellor’s of medicine? announcement demonstrated his confidence in page 6 British scientists; also that his thinking is underpinned by figures from the OSI showing that Unit profile the UK now leads the group of the eight largest Network visits the industrial nations in its biomedical and pre-clinical MRC Protein research productivity. Phosphorylation “The UK’s record in supporting world-class Unit in Dundee Chancellor Gordon Brown delivers the 2006 Budget speech medical research through the MRC is second page 10 in the House of Commons on 22 March. to none. Developments in science can be Mind the found in every aspect of our daily lives Within the first few minutes of his 2006 Budget including breakthroughs on ageing and drug gender gap speech, Chancellor Gordon Brown made clear that research.The DTI is committed to ensuring How the MRC is science – in education and research – is central to that science and innovation are at the heart of helping women the Government’s plans for the British economy in the coming decades. One of his most radical government, and that we maintain the UK’s progress in science proposals was for a single fund of more than £1 leading position in medical research.We will page 14 billion ring-fenced for the MRC and for Department build on the outstanding achievements of the of Health (DH) R&D, to support the full spectrum MRC and ensure we are facilitating the National Science of biological and clinical research in the UK. How research base in the best possible way.” Week this new arrangement will work in practice is being Alan Johnson, Secretary of State for the Department A run-down of the determined through a consultation process chaired of Trade and Industry (DTI). events organised by Sir David Cooksey and steered by the Treasury and representatives of the DH and the Office of by MRC scientists Science and Innovation (OSI; the new name of the The importance of preserving the independence this year OST), which will be reporting back in the autumn. from government enjoyed by the research councils page 18 The MRC is keen to hear a wide variety of views to is recognised. Science and innovation investment help us develop our own contribution. Comments framework 2004-2014: next steps sets out the can be made through the MRC website (see box, Government’s vision for scientific research, Plus page 2). But formal submissions should be made recognising that funding must ensure “the Stem cell science, directly to Sir David’s consultation. continued delivery of world-class basic science, new faces, according to the long-standing Haldane principle research roundup, MRC Chief Executive Colin Blakemore welcomed which states that day-to-day decisions on research MRC people the Chancellor’s news. Integrating the two funding council scientific funding must be taken at arms- and more… streams could increase the speed and efficiency length from ministers. Funding would continue to with which basic research can be translated into be awarded on the basis of excellence across the >> page 2 2 MRC | network Spring/Summer 2006 << The budget full spectrum of health research, from basic to clinical and public health.This will include continued support for investigator-led Backing new ideas in research”. clinical research Building on MRC success Experimental medicine is research that takes place at the Colin Blakemore’s hope is that the single fund will provide the interface of laboratory and patient-based studies. In recent opportunity to build on the MRC’s considerable achievements: years both the Government and the clinical research “We’re committed to supporting high-quality research across the community have drawn attention to the relative lack of entire spectrum of the biomedical and clinical sciences.We are investment in this area. In 2005 the MRC responded to these proud of our international reputation for achievement – from the concerns by making up to £15 million available for new introduction of penicillin and discovery of the structure of DNA research in experimental medicine.To help get a clear picture to the development of MRI; from the creation of blockbuster of how much funding was appropriate and where it was most antibody drugs to vital clinical trials, such as those on statins and on vaccines in Africa.” needed, the MRC invited ‘expressions of interest’ from the research community.These took the form of brief sketches The Budget statement emphasises the Treasury’s recognition of the which outlined the aims and costs of the proposed studies. crucial link between science funding and innovation. Colin Faced with almost 1,000 expressions of interest totalling Blakemore added:“Companies, universities and the public all over £350 million, the MRC Clinical Research Overview Group the UK are reaping the benefits of breakthroughs made by MRC- funded scientists.We are determined to expand that success even honed the call. Focusing on need and the best use of further. Combining the funding of the MRC and the DH will resources, it invited proposals that “evaluate a novel produce gains in efficiency and opportunities for collaboration that intervention, including an entirely novel application of an should benefit medical researchers throughout the UK.” already existing treatment in human participants with the aim to provide proof of concept.” Colin Blakemore says the MRC is looking forward to exploiting its strengths in biomedical research through continued close working In March 2006, the MRC with all the health departments, including those of Scotland,Wales awarded £15 million to and Northern Ireland.The organisation is keen to demonstrate scientists across the medical that it can respond quickly and effectively to clinical as well as research disciplines.The scientific challenges. successful applications ranged from research into the use of Developing UK science skills melatonin to reduce brain The Budget contained more good news for science in its damage in pre-term infants commitment to achieve a step change in the area of science and Blood cells infected by the and the effect of statins on the UK economy.The Government aims to create more science malaria parasite. asthma, to testing a malaria graduates and more science entrepreneurs.This chimes well with vaccine by using killer T cells against the parasite in liver cells. the MRC’s mission to sustain and develop the UK’s research capacity by training skilled scientists and supporting them at A huge boost for patient-based research, these awards will every stage of their careers. exploit the UK’s unique potential for such work. As the Government’s Next steps document points out,“few other The Next steps document points out the growing competition countries have a health service that provides researchers presented by China and India and emphasises “the need to adapt in with the potential to access virtually the entire population, order to continue to attract and retain high-value economic through an integrated system of primary, secondary and activities”. Anticipating this global scenario, the MRC is rapidly building its collaborations with scientists in China and south-east tertiary care.” Asia to ensure it can meet the health priorities and medical opportunities of the future, in the UK and around the world. Collective commitment Find out more online The MRC’s £15 million investment in experimental medicine is part of a national strategy involving partners in the UK Single health research fund web forum Clinical Research Collaboration. Other initiatives include the http://extra.mrc.ac.uk/forms/shrf funding of new clinical research infrastructure by the Science and innovation investment framework 2004–2014: next steps Wellcome Trust,The Wolfson Foundation and the Health www.hm-treasury.gov.uk/media/1E1/5E/bud06_science_332.pdf Departments, to which the MRC will contribute a number of Budget 2006 summary MRI scanners for use in experimental medicine studies. http://budget2006.treasury.gov.uk/ Spring/Summer 2006 MRC | network 3 Steps forward in stem cell science Following the International Stem Cell Forum’s meeting in January, Network brings readers an update on its work to establish and safeguard standards in stem cell science worldwide... In January 2006 members of the International Stem Cell Forum challenging task of reviewing the differing ethical and regulatory (ISCF) gathered in Paris for their fourth annual meeting, which approaches of all countries that fund stem cell science, with a was chaired by MRC Chief Executive Colin Blakemore.Topics particular emphasis on research involving embryonic stem cells. ranged from progress in international collaboration and the Future work of the group will include developing a global register of Forum’s work on standardising characterisation of stem cell lines clinical trials involving therapeutic use of stem cells. worldwide, to its new online cell registry and cooperation between stem cell banks. The importance of ethics to stem cell research was brought into sharp focus when South Korean scientist Dr Woo-Suk Hwang Key ISCF projects admitted that he had falsified his research results. Dr Hwang Members were updated on two key ISCF working group projects – published papers in Science in 2004 and 2005 claiming that he had the International Stem Cell Initiative (ISCI) and a global review of created the world’s first cloned human embryos and 11 stem cell ethics and regulation of stem cell research.
Load more

Recommended publications
  • DARIA SIEKHAUS, Ph.D
    DARIA SIEKHAUS, Ph.D. Address: Institute of Science and Technology (IST) Austria Am Campus 1 Bertalanffy Building 3400 Klosterneuburg Austria Telephone: 0043 664 886 876 96 E-mail: [email protected] Birthplace: Berkeley, California, United States Nationality: USA EDUCATION: Stanford University, Department of Biochemistry, Stanford, CA, Ph.D. 1998 Harvard and Radcliffe Colleges, Cambridge, MA, B.A. in Biology, magna cum laude, 1987 RESEARCH EXPERIENCE: Assistant Professor ‐ IST Austria. Jan 2012‐ present Research Scientist – New York University Medical Center, Skirball Institute, Dept. of Developmental Genetics Advisor: Ruth Lehmann, Ph.D. Understanding the mechanism of invasive migration in Drosophila immune cells. 2003‐2011 Post‐doctoral Fellow – University of California Berkeley, Dept. of Molecular Cell Biology Advisor: David Drubin, Ph.D. Understanding the interpretation of chemotropic gradients in S. cerevisiae through cell biological and genetic analyses. 1999‐2003 Graduate Student – Stanford University, Dept. of Biochemistry Advisors: Robert S. Fuller, Ph.D., Mark A. Krasnow, M.D. Ph.D. Identification, and genetic and functional characterization of the neuropeptide and prohormone processing proteases in Drosophila involved in hatching behavior at the end of embryogenesis. 1989-1998 Deutscher Akademischer Austauschdienst Fellow – Max Planck Institute for Biophysical Chemistry, Göttingen, Germany Advisor: Peter Gruss, Ph.D. Expression, purification and biochemical characterization of the murine neuron specific zinc finger gene,
    [Show full text]
  • Manfred Eigen: the Realization of His Vision of Biophysical Chemistry
    CORE Metadata, citation and similar papers at core.ac.uk Provided by OIST Institutional Repository Manfred Eigen: the realization of his vision of Biophysical Chemistry Author Herbert Jackle, Carmen Rotte, Peter Gruss journal or European Biophysics Journal publication title volume 47 number 4 page range 319-323 year 2017-12-11 Publisher Springer International Publishing Rights (C) 2017 The Author(s). Author's flag publisher URL http://id.nii.ac.jp/1394/00000696/ doi: info:doi/10.1007/s00249-017-1266-y Creative Commons Attribution 4.0 International (http://creativecommons.org/licenses/by/4.0/) European Biophysics Journal (2018) 47:319–323 https://doi.org/10.1007/s00249-017-1266-y REVIEW Manfred Eigen: the realization of his vision of Biophysical Chemistry Herbert Jäckle1 · Carmen Rotte1 · Peter Gruss1,2 Received: 27 August 2017 / Accepted: 11 November 2017 / Published online: 11 December 2017 © The Author(s) 2017. This article is an open access publication Abstract Manfred Eigen turned 90 on May 9th, 2017. He celebrated with a small group of colleagues and friends on behalf of the many inspired by him over his lifetime—whether scientists, artists, or philosophers. A small group of friends, because many—who by their breakthroughs have changed the face of science in diferent research areas—have already died. But it was a special day, devoted to the many genius facets of Manfred Eigen’s oeuvre, and a day to highlight the way in which he continues to exude a great, vital and unbroken passion for science as well as an insatiable curiosity beyond his own scientifc interests.
    [Show full text]
  • Trustees' Annual Report and Financial Statements 31 March 2016
    THE FRANCIS CRICK INSTITUTE LIMITED A COMPANY LIMITED BY SHARES TRUSTEES’ ANNUAL REPORT AND FINANCIAL STATEMENTS 31 MARCH 2016 Charity registration number: 1140062 Company registration number: 6885462 The Francis Crick Institute Accounts 2016 CONTENTS INSIDE THIS REPORT Trustees’ report (incorporating the Strategic report and Directors’ report) 1 Independent auditor’s report 12 Consolidated statement of financial activities 13 Balance sheets 14 Cash flow statements 15 Notes to the financial statements 16 1 TRUSTEES’ REPORT (INCORPORATING THE STRATEGIC REPORT AND DIRECTORS’ REPORT) The trustees present their annual directors’ report together with the consolidated financial statements for the charity and its subsidiary (together, ‘the Group’) for the year ended 31 March 2016, which are prepared to meet the requirements for a directors’ report and financial statements for Companies Act purposes. The financial statements comply with the Charities Act 2011, the Companies Act 2006, and the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK (FRS102) effective 1 January 2015 (Charity SORP). The trustees’ report includes the additional content required of larger charities. REFERENCE AND ADMINISTRATIVE DETAILS The Francis Crick Institute Limited (‘the charity’, ‘the Institute’ or ‘the Crick) is registered with the Charity Commission, charity number 1140062. The charity has operated and continues to operate under the name of the Francis Crick
    [Show full text]
  • Max-Planck-Institut F¸R Biophysikalische Chemie Gˆttingen
    Max Planck Institute for Biophysical Chemistry Dr. Carmen Rotte Press and Public Relations Am Faßberg 11, 37077 Göttingen, Germany Phone: +49 551 201-1304 Email: [email protected] Press Release January 13, 2014 Prestigious Chinese award for Herbert Jäckle The People's Republic of China has given its 2013 International Science and Technology Cooperation Award to the Göttingen Max Planck researcher Herbert Jäckle. This, the highest prize for foreign individuals or organizations in the field of science and technology honors the significant contributions the awardee has made to China’s social and economic development. The prize was awarded in a solemn ceremony held on January 10 in the Great Hall of the People in Beijing in the presence of Chinese Government representatives. In addition to Herbert Jäckle seven scientists and engineers from all over the world received the prestigious prize. Awardee Herbert Jäckle has strongly promoted cooperation between the Max Planck Society and the Chinese Academy of Sciences. Jäckle, who was appointed Vice President of the Max Planck Society in 2002, has provided creative ideas which have altered both the Chinese and the German scientific landscape and strengthened international cooperation. The Partner Institute for Computational Biology in Shanghai (China) – jointly supported by the Max Planck Society and the Chinese Academy of Sciences – was established in 2005 on his initiative. Jäckle has further developed a new and very Photo: Böttcher-Gajewski / Max Planck Institute for successful concept for promotion of junior Biophysical Chemistry scientists within the Max Planck Society. This concept was also implemented at the Partner Institute in Shanghai to support talented young researchers early in their scientific careers.
    [Show full text]
  • Booklet Peter Gruss.Pdf
    KAPITELÜBERSCHRIFT INHALTSVERZEICHNIS IMPRESSUM 05 Erneuerungsfähigkeit der Max-Planck-Gesellschaft stärken Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. 27 Exzellente Köpfe gewinnen Hofgartenstr. 8, D - 80539 München Tel.: +49 (0) 89 2108-1276 39 Internationale Sichtbarkeit erhöhen E-Mail: [email protected] Internet: www.mpg.de 47 Deutsches Wissenschaftssystem voranbringen Redaktion 55 Finanzierung sichern Iris Karabelas / Mechthild Schmid 63 Anliegen der Wissenschaft in Politik und Öffentlichkeit vermitteln Grafiken Dalija Budimlic 71 Offenen Zugang zu Forschungsergebnissen ermöglichen Gestaltung 77 Wissenschaft und Wirtschaft zusammenführen HAAK & NAKAT, München [www.haak-nakat.de] 87 Chronik, Weitere Funktionsträger an der Seite des Präsidenten, Vita 3 ERNEUERUNGSFÄHIGKEIT DER MAX-PLANCK-GESELLSCHAFT STÄRKEN 1 80% DER NEUBERUFUNGEN SIND NICHT IM FELD DES VOrgÄNgers ERNEUERUNGSFÄHIGKEIT DER MAX-PLANCK-GESELLSCHAFT STÄRKEN PERSPEKTIVENKOMMISSION THEMEN REDE VOR DEM WISSENSCHAFTLICHEN RAT kommissionen gesteuert. Es war ein wichti- 19.02.2009 ger Schritt, die perspektivische Planung der Oft wird von außen übersehen, dass die Max- Max-Planck-Gesellschaft auf eine breite, und Planck-Gesellschaft weit mehr ist als die Sum- zwar Max-Planck-weite Basis zu stellen – sozu- me ihrer Institute. Die Max-Planck-Gesellschaft sagen den Max-Planck-Organismus zu kräfti- ist vielmehr ein Organismus, der sich aus dem gen! Mittlerweile haben alle drei Sektionen Zusammenwirken ihrer Wissenschaftlerinnen Perspektivenkommissionen eingerichtet, die die und Wissenschaftler bildet. Das einzelne Max- Konzepte der Institute im Bezug auf die ganze BERATUNGSPROZESS Planck-Institut ist kein Satellit, der auf Dauer Sektion betrachten. erfolgreich alleine fliegen kann oder gar abge- Die Aufgabenstellung und der Grad der perspek- trennt an einer anderen Einrichtung erfolgreich tivischen Analyse in der Perspektivenkommissi- weiterbestehen könnte.
    [Show full text]
  • Editor European Editor Senior Editors Consulting Editor Managing
    CORE Metadata, citation and similar papers at core.ac.uk Provided by Elsevier - Publisher Connector Cell Editor Associate Editors Benjamin Lewin Richard Axel Philippa Marrack Rosa Beddington Chris Marshall European Editor Pierre Chambon Diane Mathis Peter W. J. Rigby Joanne Chory Ira Mellman Julian Downward Don Metcalf Senior Editors David Friedman Elliot Meyerowitz Amy Axelrod Phillip Gallimore Tim Mitchison Vivian Siegel John Gerhart Paul Nurse Stephen Goff William Paul Joe Goldstein Hugh Pelham Consulting Editor Peter Goodfellow Roger Perlmutter Gregory Gasic Peter Gruss Klaus Rajewsky Martin Hemier Danny Reinberg Managing Editor Ira Herskowitz James Roberts Rebecca Kennison Chris Higgins Elliott Ross Robert Horvitz Gerald Rubin Editorial Staff Tim Hunt Joshua Sanes Alexander Barnett Tony Hunter Jeff Schell Edward J. Dionne Richard Hynes Matthew Scott Jennifer MacMillan David Ish-Horowitz David Sherratt Martha Sullivan Thomas Jesse11 Jim Smith Peter Kim Frank Solomon Judith Kimble Davor Solter Advertising Roger Kornberg George Sprague Lynn Reznick Parisi - Director John Kuriyan Charles Stevens Jennifer Oneglia - Classifieds Ron Laskey Robert Tjian Christa A. Matukaitis Michael Levine Richard Treisman Richard Losick Mike Waterfield Circulation Vivek Malhotra Alan Weiner Marie Arsenault - Manager Tom Maniatis Owen Witte Heather L. McCormick Telephone Numbers Principal Office European Office Cell Division of Eukaryotic Editorial: 617-661-7057 1050 Massachusetts Avenue Molecular Genetics Advertising: 617-661-7059 Cambridge, Massachusetts 02138 NIMR USA The Ridgeway, Mill Hill Subscriptions: 617-661-7060 Fax: 617-661-7061 London NW7 1 AA, England E-mail: [email protected] Telephone: (0)181-906-3897 Fax: (0)181-913-8527 E-mail: [email protected] Cell (ISSN 0092-8674) is published biweekly by Cell Press, 1050 Massachusetts Avenue, Cambridge, Massachusetts 02138.
    [Show full text]
  • Event PDF Brochure V2
    OIST FOUNDATION Year Anniversary Gala December 2, 2020 From 6:30 PM EST ABOUT THE OIST FOUNDATION & OIST OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY FOUNDATION OIST FOUNDATION www.oistfoundation.org The Okinawa Institute of Science and Technology Foundation, Inc., a 501(c)3 non-profit organization, promotes innovative global scientific breakthroughs through enhancing and strengthening science and technology research and related programs at the Okinawa Institute of Science and Technology Graduate University (OIST) and empowers Americans to support the sustainable development of Okinawa and deepen U.S.-Japan relations through OIST. OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY GRADUATE UNIVERSITY OIST www.oist.jp The Okinawa Institute of Science and Technology Graduate University (OIST) is an interdisciplinary graduate school offering a 5-year Ph.D. program in Science. OIST was founded by the Japanese government to contribute to science and technology worldwide, attract leading researchers from Japan and abroad to conduct high-quality research, advance the development of a world-class research hub, and nucleate a knowledge cluster that will catalyze technology transfer and industrial innovation in Okinawa. OIST Foundation First Year Anniversary Gala 02 THE EVENT WELCOMING REMARKS OIST FOUNDATION FIRST ANNIVERSARY GALA MESSAGES David P. Janes, Managing Director, OIST Foundation Minister Taro Kono, Minister of State for Okinawa and Northern GALA PERFORMANCE Territory Affairs Ambassador Extraordinary Ms. Eiko Kano, Violinist and OIST Foundation Music Ambassador Shinsuke J. Sugiyama, Ambassador and Plenipotentiary of Japan to the United States Consul General of the United States to Mr. Karén Hakobyan, Pianist and Founder, Pegasus: Hon. Robert Koepcke, The Orchestra Naha, Okinawa FUTURE OF SCIENCE & TECHNOLOGY ROUNDTABLE REMARKS MODERATOR Amb.
    [Show full text]
  • Garching Information 1/05
    Garching Innovation GmbH Technologien aus der Max-Planck-Gesellschaft Contents: Welcome ”Viewpoint” – Guest Column Prof. Dr. Peter Gruss, President of the Max Planck Society /05 News 1 MPS Start-up Profile Aurigon Life Science GmbH Technology Offers More than 30 years of technology transfer experience Dr. Bernhard Hertel, Managing Director of Garching Innovation GmbH Garching Innovation – Internal Matters Upcoming Events Frequently Asked Questions Information Contact Imprint Our Technology Transfer Activities for the Max Planck Society Seite 1 1 Garching Garching Innovation GmbH Technologien aus der Max-Planck-Gesellschaft Contents: Dear Reader, Together with our new web site, we are pleased to present 1/0 5 Welcome the first edition of GarchingInformation. This newsletter will be published online regularly and will serve as a forum ”Viewpoint” – Guest Column for reporting the latest news on our technology transfer Prof. Dr. Peter Gruss, elcome activities. President of the W Our target group is as diverse as our business. For this Information Max Planck Society reason, we have designed the various columns of our news- letter with the aim of appealing not only to scientists, inven- News tors and potential founders in the Max Planck Institutes, but Garching also to investors, industry and cooperation partners, as well MPS Start-up Profile as other network partners. Aurigon Life Science GmbH In an effort to provide widely differing perspectives on current issues related to technology transfer, we will ask Technology Offers representatives from research, politics, industry and inves- tors to share their ”Viewpoint” in a guest column. We are More than 30 years of very pleased that Prof.
    [Show full text]
  • Annual Report 2011
    ANNUAL REPORT 2011 www.germaninnovation.org 2 The German Center for Research and Innovation New York (GCRI) is a joint initiative of Germany’s Federal Foreign Office and its Federal Ministry of Education and Research. In its first two years of operation, GCRI has significantly enhanced the visibility of the German research and innovation landscape in North America, leading to new collaborative projects, investments in German technology, and an enhanced media presence for Germany in North America. GCRI’s areas of focus mirror those of Germany’s High-Tech Strategy, and include: Climate and Energy • Health and Nutrition • Mobility • Security • Communication In addition, GCRI has also led the transatlantic dialogue in emerging and evolving areas, such as nanotechnology, biotechnology, and medical technologies. Over 70% of GCRI’s activities in 2011 concentrated on the aforementioned areas of focus. These activities included panel discussions, symposia, exhibitions, and conferences. GCRI leveraged multiple communications media, including publishing a monthly newsletter, distributing press releases about significant developments and events, and posting on various Internet social media outlets. The Center’s dynamic website documents GCRI’s myriad activities and serves as an information platform for the German research and innovation landscape and funding sources. Over the past year, the Center’s website has registered visitors from 146 countries seeking information regarding job postings, funding opportunities for research in Germany, German innovation centers and technology parks, and general news feeds from Germany. GCRI’s most recent project is the creation of the GCRI Foundation, a 501©3, which will begin operations in 2012, with a Board of Directors from leading German and American companies.
    [Show full text]
  • Annual Report 2016 IST Austria Annual Report 2016 an International Community Content the Scientists of IST Austria
    Annual Report 2016 IST Austria Annual Report 2016 An International Community Content The Scientists of IST Austria Introduction Research 06 Foreword by the President 26 Research at IST Austria 55 Novarino Group 08 Guest Commentary by Alice Dautry 28 Barton Group 56 Pietrzak Group 29 Benková Group 57 Sazanov Group The Institute 30 Bickel Group 58 Seiringer Group 12 IST Austria at a Glance 31 Bollback Group 59 Shigemoto Group 32 Bollenbach Group 60 Siegert Group Highlights 33 Chatterjee Group 61 Siekhaus Group 16 Assessing Progress 34 Cremer Group 62 Sixt Group 18 The Essentials for Future Success 35 Csicsvari Group 63 Tkačik Group 20 Research Highlight Mathematics 36 Edelsbrunner Group 64 Uhler Group 37 Erdős Group 65 Vicoso Group 38 Fink group 66 Wagner Group 39 Friml Group 67 Wojtan Group 40 Guet Group 68 New Professors 41 Hausel Group 70 Grants, Awards & Prizes 42 Heisenberg Group 72 Publications 43 Henzinger Group 44 Hippenmeyer Group Outreach 45 Hof Group 80 Scientific Events 46 Janovjak Group 82 Public Events 47 Jonas Group 48 Katsaros Group Organization 49 Kicheva Group 86 Donors 50 Kolmogorov Group 88 Technology Transfer 51 Lampert Group 90 Scientific Service Units 52 Lemeshko Group 94 Administration 53 Loose Group 96 Boards of IST Austria 54 Maas Group 97 Location & Directions Scientists from all over the world come to IST Austria. This map gives an overview of the nationalities on campus. IST Austria Scientists IST Austria Scientists by Previous Institution by Nationality Austria 17.0% Austria 13.8% Germany 13.8% Germany 11.9% UK 7.2% Italy 5.7% Italy 4.7% Slovakia 5.7% USA 4.7% China 5.3% Czech Republic 4.4% Czech Republic 5.3% France 4.4% Russia 4.4% Switzerland 4.1% Hungary 4.1% Spain 3.8% India 4.1% Russia 3.5% Poland 3.5% China 3.1% France 3.1% Hungary 2.5% Spain 3.1% India 2.5% other 30.0% Japan 2.5% other 21.8% 4 | IST Austria Annual Report 2016 6 | IST Austria Annual Report 2016 Introduction | 7 Foreword Thomas A.
    [Show full text]
  • Annual Report and Financial Statements
    THE FRANCIS CRICK INSTITUTE LIMITED A COMPANY LIMITED BY SHARES ANNUAL REPORT AND FINANCIAL STATEMENTS 31 March 2017 Charity registration number: 1140062 Company registration number: 6885462 WHO WE ARE CONTENTS The Francis Crick Institute is a Trustees’ report (incorporating the strategic report and biomedical discovery institute dedicated directors’ report) 1 to understanding the fundamental Independent auditor’s report 10 biology underlying health and illness. Consolidated statement Our work is helping to understand why of financial activities 11 disease develops and to translate this Balance sheets 12 into new ways to prevent, diagnose and Cash flow statements 13 treat illnesses such as cancer, heart disease, strokes, infections, and Notes to the financialstatements 14 neurodegenerative diseases. For more information www.crick.ac.uk TRUSTEES’ REPORT (INCORPORATING THE STRATEGIC REPORT AND DIRECTORS’ REPORT) The trustees present their annual directors’ report together with the consolidated financial statements for the charity and its subsidiary (together, ‘the Group’) for the year ended 31 March 2017, which are prepared to meet the requirements for a directors’ report and financial statements for Companies Act purposes. The financial statements comply with the Charities Act 2011, the Companies Act 2006, and the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK (FRS102) effective 1 January 2015 (Charity SORP). The trustees’ report includes the additional content required of larger charities. REFERENCE AND ADMINISTRATIVE DETAILS The Francis Crick Institute Limited (‘the charity’, ‘the institute’ or ‘the Crick’) is registered with the Charity Commission, charity number 1140062. The charity has operated and continues to operate under the name of the Francis Crick Institute.
    [Show full text]
  • The Medical Research Council's Review of the Future of the National Institute for Medical Research
    House of Commons Science and Technology Committee The Medical Research Council's Review of the Future of the National Institute for Medical Research Fourth Report of Session 2004–05 Volume I HC 6-I House of Commons Science and Technology Committee The Medical Research Council's Review of the Future of the National Institute for Medical Research Fourth Report of Session 2004–05 Volume I Report Ordered by The House of Commons to be printed 26 January 2005 HC 6-I Published on 8 February 2005 by authority of the House of Commons London: The Stationery Office Limited £0.00 The Science and Technology Committee The Science and Technology Committee is appointed by the House of Commons to examine the expenditure, administration and policy of the Office of Science and Technology and its associated public bodies. Current membership Dr Ian Gibson MP (Labour, Norwich North) (Chairman) Paul Farrelly MP (Labour, Newcastle-under-Lyme) Dr Evan Harris MP (Liberal Democrat, Oxford West & Abingdon) Kate Hoey MP (Labour, Vauxhall) Dr Brian Iddon MP (Labour, Bolton South East) Mr Robert Key MP (Conservative, Salisbury) Mr Tony McWalter MP (Labour, Hemel Hempstead) Dr Andrew Murrison MP (Conservative, Westbury) Geraldine Smith MP (Labour, Morecambe and Lunesdale) Bob Spink MP (Conservative, Castle Point) Dr Desmond Turner MP (Labour, Brighton Kemptown) Powers The Committee is one of the departmental Select Committees, the powers of which are set out in House of Commons Standing Orders, principally in SO No.152. These are available on the Internet via www.parliament.uk Publications The Reports and evidence of the Committee are published by The Stationery Office by Order of the House.
    [Show full text]